Dave Lennon's CEO adventure goes from preclinical to commercial; GSK vet embarks on new Odyssey with Gary Glick

After stepping into the CEO post for the first time about two years ago, taking over the helm of “tissue therapeutics” startup Satellite Bio, Dave Lennon is ready to take on his next challenge in the C-suite.

On Monday, he traded hats from the preclinical Boston startup for the commercial-stage Los Angeles drugmaker Aadi Bioscience. About a year and a half into the launch of its ultra-rare sarcoma drug Fyarro, Aadi has big label expansion plans.

Preview

来源: EndPoints

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP

LOG IN

BECOME A PREMIUM SUBSCRIBER

更多内容，请访问原始网站

文中所述内容并不反映新药情报库及其所属公司任何意见及观点，如有版权侵扰或错误之处，请及时联系我们，我们会在24小时内配合处理。